期刊
CYTOKINE
卷 57, 期 2, 页码 290-293出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.cyto.2011.11.018
关键词
CML; Imatinib; IFN-alpha; Stopping
Imatinib (IM) is the current first line treatment for chronic myeloid leukemia (CML). However, the disease will progress in the majority of patients pausing IM. IFN-alpha may intensify the response and increase the percentage of patients maintaining remission after IM cessation. Eleven patients with stable (>= 2 years) complete cytogenetic responses (CCyR) on IM therapy were recruited to the study. They were administered Peg-IFN-alpha for 9 months before and for 3 months following IM discontinuation. During the 12 months of Peg-IFN-alpha therapy the remission status improved in five (45%) of the patients. Six (55%) of the patients experienced cytogenetic relapses at a median period of 8 months (range 2-33) after IM withdrawal. All six patients regained CCyR following IM restart. With a median follow up of 47 months (range 35-50), five (45%) out of the 11 studied patients maintain cytogenetic response off IM therapy. The role of Peg-IFN-alpha in patients pausing IM is to be further evaluated. This study is registered with ClinicalTrials.gov, number NCT00297570. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据